Evidence map›Paper›PMID 35988454›Full record

ArticleESMO open2022

Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.

R Soo, L Mery, A Bardot, R Kanesvaran, T C Keong, D Pongnikorn, N Prasongsook, S H Hutajulu, C Irawan, A Ab Manan and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 7 countries.

R SooDepartment of Hematology-Oncology, National University Hospital, Singapore, Singapore.
L MerySection of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
A BardotSection of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
R KanesvaranDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
T C KeongDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
D PongnikornCancer Registry Unit, Lampang Cancer Hospital, Lampang, Thailand.
N PrasongsookMedical Oncology Division, Department of Internal Medicine, Phramongkutklao Hospital, Bangkok, Thailand.
S H HutajuluDivision of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
C IrawanDivision of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
A Ab MananMalaysian National Cancer Registry Department, National Cancer Institute, Ministry of Health Malaysia, Putrajaya, Malaysia.
M ThiagarajanDepartment of Radiotherapy and Oncology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia.
P SripanResearch Institute for Health Sciences, Chiang Mai University, Chiangmai, Thailand.
S PetersDepartment of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
H StormDanish Cancer Society, Copenhagen, Denmark.
F BraySection of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
R StahelETOP IBCSG Partners Foundation, Bern, Switzerland. Electronic address: Rolf.Stahel@etop.ibcsg.org.
Centre International de Recherche sur le Cancer · FRNational Cancer Centre Singapore · SGChiang Mai University · THDanish Cancer Society · DKHospital Kuala Lumpur · MYInternational Breast Cancer Study Group · CHLampang Cancer Hospital · THNational Cancer Institute · MYNational University Hospital · SGPhramongkutklao Hospital · THUniversitas Gadjah Mada · IDUniversity Hospital of Lausanne · CHUniversity of Indonesia · ID

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundLung cancer is the second most common cancer and leading cause of cancer mortality worldwide. Recent advances in molecular testing and targeted therapy have improved survival among patients with metastatic non-small-cell lung cancer (NSCLC). We sought to quantify and describe molecular testing among metastatic non-squamous NSCLC cases in selected Southeast Asian countries and describe first-line therapy chosen. PATIENTS AND

methodsA retrospective study was conducted based on incident lung cancer cases diagnosed between 2017 and 2019 in Lampang (Thailand), Penang (Malaysia), Singapore and Yogyakarta (Indonesia). Cases (n = 3413) were defined using the International Classification of Diseases for Oncology third edition. In Singapore, a clinical series obtained from the National Cancer Centre was used to identify patients, while corresponding population-based cancer registries were used elsewhere. Tumor and clinical information were abstracted by chart review according to a predefined study protocol. Molecular testing of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) gene rearrangement, ROS1 gene rearrangement and BRAF V600 mutation was recorded.

resultsAmong 2962 cases with a specified pathological diagnosis (86.8%), most patients had non-squamous NSCLC (75.8%). For cases with staging information (92.1%), the majority presented with metastatic disease (71.3%). Overall, molecular testing rates in the 1528 patients with stage IV non-squamous NSCLC were 67.0% for EGFR, 42.3% for ALK, 39.1% for ROS1, 7.8% for BRAF and 36.1% for PD-L1. Among these patients, first-line systemic treatment included chemotherapy (25.9%), targeted therapy (35.6%) and immunotherapy (5.9%), with 31% of patients having no record of antitumor treatment. Molecular testing and the proportion of patients receiving treatment were highly heterogenous between the regions.

conclusionsThis first analysis of data from a clinically annotated registry for lung cancer from four settings in Southeast Asia has demonstrated the feasibility of integrating clinical data within population-based cancer registries. Our study results identify areas where further development could improve patient access to optimal treatment.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnaplastic Lymphoma KinaseB7-H1 AntigenErbB ReceptorsHumansMutationProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins B-rafRetrospective StudiesThailandAnaplastic Lymphoma KinaseB7-H1 AntigenErbB ReceptorsProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins B-rafAsialung cancermolecular testingNSCLCpopulation-based cancer registry

Identifiers

PMID35988454
PMCPMC9588878
OpenAlexW4292677073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.